Replicel

   
Share/Bookmark
 
Avatar

517

RankRank

Editor

Total Posts: 108

Member Since:
January 2010

May 02, 2012, 12:15 PM

This is from an email I received

Below is an excerpt from the RepliCel Life Sciences Inc. May 2nd news release titled “RepliCel Releases Positive Results from the Interim Analysis of Data from its First-in-man TS001-2009 Clinical Trial”.
>
>  
>
> May 2, 2012
>
> By RepliCel on May 2, 2012
>
> VANCOUVER, BC – May 2, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) is pleased to report positive results from its interim analysis of six-month post-injection data collected from its first-in-man clinical trial (TS001-2009) designed to test the safety and efficacy of the RepliCel™ technology in men and women with androgenetic alopecia (pattern baldness). The primary protocol objective of the study is to assess the local (at treatment sites) safety profile of injections of autologous dermal sheath cup cells (DSCC) at six months post-injection compared to placebo. Secondary protocol objectives are to assess systemic (overall) safety and efficacy (hair growth at treatment sites) at 6 and 24 months post-injection and local safety at 24 months post-injection. The six-month interim analysis was designed to provide the Company with safety information to support the regulatory filing for a Phase IIb clinical trial…
>
> To view the full May 2nd news release, please visit http://www.replicel.com/replicel-releases-positive-results-from-the-interim-analysis-of-data-from-its-first-in-man-ts001-2009-clinical-trial/ .
>
> Kind Regards,
>
> RepliCel Life Sciences
>
> Tammey George, Director of Communications
>
> Dir: 604.248. 8696   Email: .(JavaScript must be enabled to view this email address)
>
> http://www.replicel.com

 

IGNORE

 
   
 








THE INTERNET'S HOME FOR

HAIR LOSS NEWS, TREATMENTS, SOLUTIONS, AND FORUMS.